Indeed, CSF analysis provides indirect signs to a broader range of diagnoses than AD since amyloid and tau biomarkers might also be altered in different pathological situations such as non-Alzheimer's neurodegenerative diseases like DLB, FTLD and Creutzfeldt-Jakob disease (Gabelle et al. 2011; Bousiges et al. 2018; Bibl et al. 2008; Lehmann et al. 2019) as well as brain damage (Alosco et al. 2018), normal pressure hydrocephalus (Manniche et al. 2020) and cerebral amyloid angiopathy (Renard et al. 2012) 19. This evidence concerns the gene MAPT and Alzheimer disease.